Opolskie Centrum Onkologii Im. Prof. Tadeusza Koszarowskiego W Opolu Samodzielny Publiczny Zaklad Opieki Zdrowotnej
- Address
- lock Available on a paid plan
Cardiovascular Disease Research
The Opolskie Centrum Onkologii conducts focused investigations on heart health, especially the impact of cancer treatments on cardiac function. One major effort evaluates whether sacubitril/valsartan can prevent treatment‑related heart damage in breast cancer patients, while another study monitors recovery in individuals with post‑anthracycline cardiomyopathy. These trials aim to improve safety and long‑term outcomes for patients receiving potentially cardiotoxic therapies.
- Prevention of chemotherapy‑induced cardiotoxicity
- Management of heart failure after anthracycline exposure
- Assessment of cardiac function biomarkers
- Integration of cardiology care into oncology pathways
By addressing cardiovascular risks, the site supports a holistic approach to cancer care, ensuring that life‑extending treatments do not compromise heart health.
Oncology Research
A broad spectrum of trials at the clinic targets neoplasms, with a particular emphasis on breast, colorectal, gastric, lung, prostate and other solid tumors. Researchers test novel targeted agents, immunotherapies, and combination regimens to enhance survival and reduce disease recurrence. Studies range from early‑stage adjuvant therapies for hormone‑receptor‑positive breast cancer to advanced‑line options for metastatic triple‑negative disease and HER2‑positive gastric cancer.
- Triple‑negative breast cancer therapies
- HER2‑positive breast and gastric cancer treatments
- KRAS/NRAS/BRAF wild‑type colorectal cancer trials
- Metastatic castration‑resistant prostate cancer studies
- FGFR2b‑positive gastric and gastro‑esophageal junction cancer
- Non‑small cell lung cancer investigations
- Biomarker‑driven personalized medicine approaches
The overarching goal is to bring innovative oncology solutions to patients in Opole, offering new options that may improve progression‑free and overall survival across multiple cancer types.
Multidisciplinary and Emerging Therapies
Beyond disease‑specific studies, the centre engages in cross‑cutting research that combines chemotherapy, targeted agents, and immunomodulators. Trials explore gene‑expression‑guided treatment decisions, novel antibody‑drug conjugates, and dose‑optimization strategies to refine therapeutic windows. This platform supports rapid evaluation of cutting‑edge medicines and fosters collaboration between oncology, cardiology and translational science.
- Combination regimens with checkpoint inhibitors
- Antibody‑drug conjugate safety and efficacy assessments
- Gene‑expression (Prosigna®) driven adjuvant therapy decisions
- Phase I/II dose‑finding studies for investigational agents
- Real‑world effectiveness comparisons with standard of care
These interdisciplinary efforts aim to accelerate the translation of novel concepts into practical treatments, enhancing the therapeutic landscape for patients with complex or refractory cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 89 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 89 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Opolskie Centrum Onkologii Im. Prof. Tadeusza Koszarowskiego W Opolu Samodzielny Publiczny Zaklad Opieki Zdrowotnej
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 89 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 9 | Unknown | 2019-07-11 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.